Supporting Information

Pd-Catalyzed Regio-, Diastereo-, and Enantioselective [3+2] Cycloaddition Reactions: Access to Chiral Cyclopentyl Sulfones

Barry M. Trost,* Chuanle Zhu,¹ Chloe Christine Ence¹ Department of Chemistry, Stanford University, Stanford, CA 94305-5080, USA E-mail: bmtrost@stanford.edu

A. General Information	.2
B. Source of the Acceptors and Sulfone Donors	3
C. References	.8
D. General Procedure for the [3+2] Cycloaddition of Sulfone-TMM Donors and Acceptors .	.8
E. Analysis Data for the Obtained Products	.9
F. X-Ray Crystallographic Data	22
G. NMR Spectra of New Compounds	24

A. General Information

Unless otherwise noted, all reagents were purchased commercially and used as received. Anhydrous tetrahydrofuran (THF) was obtained by distillation from sodium/benzophenone and anhydrous toluene (PhMe) was obtained by distillation from sodium. Anhydrous 1.4-dioxane were purchased as such from Acros Organics in AcroSeal bottles and were used as received. When performing airsensitive reactions, reagents and solvents were transferred using either stainless steel cannulae or plastic syringes equipped with stainless steel needles. Air-sensitive reactions were performed under a positive pressure of either nitrogen (N₂) or argon (Ar) in reaction vessels sealed with rubber septa. Analytical thin-layer chromatography (TLC) was performed on glass-backed silica-coated plates (Merck TLC Silica gel 60 F254). Visualization was typically performed using UV light and/or basic potassium permanganate (KMnO₄). Purification by flash column chromatography was performed on silica gel (Fisher Scientific, 230-400 mesh, grade 60) using bulk solvents. Proton nuclear magnetic resonance (¹H NMR) spectra were recorded at 400 MHz using a Varian Mercury 400 spectrometer. All ¹H chemical shifts are reported in ppm relative to tetramethylsilane (0.00 ppm) or the residual solvent peak (7.264 ppm for CDCl₃, 5.32 ppm for CH₂Cl₂). Multiplets were assigned with the assistance of the multiplet tool in Mestrenova, and are abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, brs = broad, app. = apparent. Carbon nuclear magnetic resonance (13C NMR) spectra were recorded at 101 MHz using a Varian Mercury 400 spectrometer. All ¹³C chemical shifts are reported in ppm relative to the center of the residual solvent peak (77.16 ppm for CDCl₃, 53.84 ppm for CH₂Cl₂). Infrared (IR) spectra were recorded on NaCl plates using a Perkin Elmer Paragon 500 FT-IR spectrometer. Enantiomeric excess (ee) were determined by high performance liquid chromatography (HPLC) using an Agilent 1200 series HPLC system using the specified separation conditions. Optical rotations were measured on a Jasco DIP-1000 digital polarimeter using 5 cm glass cells with a Na 589 nm filter. High resolution mass spectrometry (HRMS) was performed at University of Illinois at Urbana-Champaign on a highresolution mass spectrometer (TOF). X-Ray crystallographic analysis was performed at University of Notre Dame on a Bruker APEX-II diffractometer. For reactions that require heating, all the report reaction temperature are oil bath temperature.

B. Source of the Acceptors and Sulfone Donors



Compounds 1a,¹ 1b,² 1c,² 1d,³ 1e,² 1f, 1g,² 1h,² 1i,⁴ 1j⁵ were synthesized according reported literatures.

A new compound 1k was synthesized according to the procedure for the synthesis of 1i.⁴

(E)-1,1-bis(4-Methoxyphenyl)-N-(2-nitrovinyl)methanimine (1k)



To a 100 mL round bottom flask equipped with a magnetic stir bar was dissolved bis(4methoxyphenyl)methanone (6.05 g, 25 mmol) and ethanolamine (7.625 g, 125 mmol) in benzene (25 mL) followed by acetic acid (25 μ L). The solution was equipped with a Dean-Stark trap and heated at reflux (120 °C) for 18 h. The solution was cooled to r.t. and was extracted with EtOAc (25 mL x 2) and H₂O. The organic phase was washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo. The clear colorless crude oil was sufficiently pure and carried on without further purification.

The bis(4-methoxyphenyl)methanone imine and Et₃N (3.03 g, 30 mmol) was dissolved in DCM (50

mL) in a 250 mL round bottom flask equipped with a magnetic stir bar. The solution was cooled to 0 °C and MsCl (3.01 g, 26.25 mmol) was added slowly. The mixture was gradually warmed up to r.t. and stirred for 30 mins. The mixture was diluted with DCM (20 mL) and quenched with H_2O (10 mL). The organic phase was extracted with H_2O (20 mL), washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo to afford the crude mesylate product, which was carried on without further purification.

To a 150 mL round bottom flask equipped with a magnetic stir bar was suspended *t*-BuOK (4.2 g, 37.5 mmol) in THF (50 mL). The solution was cooled to 0 °C with vigorous stirring. The obtained mesylate dissolved in THF (15 mL) was introduced slowly. The mixture was warmed to room temperature and stirred for 1 h. The viscous mixture was diluted with EtOAc (20 mL) and quenched with H_2O (10 mL). The organic phase was extracted, washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo to afford the crude enamine product as a yellow oil, which was carried on without further purification.

The obtained crude enamine, silver nitrite (9.23 g, 60 mmol), TEMPO (0.94 g, 6 mmol) and 4Å MS (6.1 g) was taken up in DCE (50 mL) in a sealed tube and heated to 70 °C for 18 h. The reaction mixture was then cooled to room temperature and then filtered through celite. Removal of the solvent, then purification via flash silica gel chromatography (5% diethyl ether in petroleum ether) afforded a yellow solid 2.81 g, 36% yield.

¹**H NMR** (400 MHz, CDCl₃): δ 7.54 (d, *J* = 11.2 Hz, 1H). 7.05 (d, *J* = 8.4 Hz, 1H), 6.73-6.75 (m, 4H), 6.23-6.25 (m, 4H), 3.16 (s, 6H).

¹³C NMR (100 MHz, CD Cl₃): δ 177.1, 161.8, 148.7, 134.7, 131.5, 113.3, 112.7, 54.8. IR (film): 3072, 2935, 2839, 2566, 2299, 2045, 1935, 1644, 1256, 1170 cm⁻¹.

HRMS (ESI-TOF, m/z): $[M+H]^+$ Calcd. for $C_{17}H_{17}N_2O_4$, 313.1188; found, 313.1176.

General Procedures for the Synthesis of Sulfone Donors:



To a 10 mL vial was added thiol (2 mmol, 1 equiv), K_2CO_3 (552 mg, 4 mmol), 2-(bromomethyl)allyl *tert*-butyl carbonate (504 mg, 2 mmol) and acetone (5 mL). The resulting mixture was sealed with a cap and stirred at room temperature for 12 h. Then the reaction mixture was filtered through a pad of silica gel and washed with EtOAc (20 mL). The filtrate was concentrated in vacuo to give **A**, which was used without purification.

The obtained crude of **A** was dissolved in CH₂Cl₂ (20 mL) and cooled to 4 °C. To the mixture was added 3-chlorobenzoperoxoic acid (*m*-CPBA) (1.341 g, 77% purity, 6 mmol) in two portions in 5 minutes. The resulting mixture was stirred at 4 °C for 1 h and quenched with saturated aqueous Na₂SO₃ solution (15 mL). After the layers were separated, the aqueous layer was extracted with CH₂Cl₂ (20 mL \times 2), and the combined organic layers were washed with 1 M K₂CO₃ solution (20 mL \times 2), H₂O (20 mL), dried over anhydrous Na₂SO₄ and the solvent was removed under reduced pressure to give the crude product, which was purified by silica gel column chromatography (petroleum ether/ethyl acetate) to afford sulfone donors **2**.

tert-Butyl (2-((pyridin-2-ylsulfonyl)methyl)allyl) carbonate (2a)



From pyridine-2-thiol (2.22 g, 20 mmol, 1 equiv) under the general procedure. The crude mixture was subjected to flash silica column chromatography (petroleum ether/EtOAc = 3:1) to yield the

title compound 2a (4.382 g, 70% yield) as white solid.

¹**H NMR** (400 MHz, CDCl₃): δ 8.75-8.76 (m, 1H), 8.04-8.06 (m, 1H), 7.93-7.96 (m, 1H), 7.52-7.56 (m, 1H), 5.37 (s, 1H), 5.09 (s, 1H), 4.62 (s, 2H), 4.19 (s, 2H), 1.46 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 156.4, 152.9, 150.2, 138.0, 131.5, 127.5, 123.6, 122.9, 82.5, 68.1, 55.2, 27.7.

IR (film): 2981, 1743, 1579, 1455, 1428, 1395, 1280 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+Na]⁺ Calcd. for C₁₄H₁₉NO₅SNa, 336.0882; found, 336.0868.

tert-Butyl (2-((pyrimidin-2-ylsulfonyl)methyl)allyl) carbonate (2b)



From pyrimidine-2-thiol (448 mg, 4 mmol, 1 equiv) under the general procedure. The crude mixture was subjected to flash silica column chromatography (petroleum ether/EtOAc = 1:1) to yield the title compound **2b** (552.6 mg, 44% yield) as clear oil.

¹**H NMR** (400 MHz, CDCl₃): δ 8.95 (d, *J* = 4.8 Hz, 2H), 7.56 (t, *J* = 4.8 Hz, 1H), 5.47 (s, 1H), 5.31

(s, 1H), 4.68 (s, 2H), 4.33 (s, 2H), 1.46 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 158.6, 152.9, 131.0, 124.4, 123.8, 82.6, 68.3, 54.6, 27.7.

IR (film): 2982, 2936, 1742, 1565, 1458, 1436, 1387, 1280 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+Na]⁺ Calcd. for C₁₃H₁₈N₂O₅SNa, 337.0834; found, 337.0825.

tert-Butyl (2-((phenylsulfonyl)methyl)allyl) carbonate (2c)

2c

From benzenethiol (220 mg, 2 mmol, 1 equiv) under the general procedure. The crude mixture was subjected to flash silica column chromatography (petroleum ether/EtOAc = 4:1) to yield the title compound 2c (443.1 mg, 71% yield) as white solid.

¹**H NMR** (400 MHz, CDCl₃): δ 7.87 (d, *J* = 7.2 Hz, 2H), 7.64 (t, *J* = 7.6 Hz, 1H), 7.54 (t, *J* = 7.6 Hz, 2H), 5.38 (s, 1H), 5.00 (s, 1H), 4.58 (s, 2H), 3.85 (s, 2H), 1.46 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 152.9, 138.0, 133.9, 132.0, 129.1, 128.5, 123.3, 82.6, 68.0, 59.8,

27.7.

IR (film): 3065, 2982, 2933, 1741, 1653, 1448, 1369, 1279, 1155 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+Na]⁺ Calcd. for C₁₅H₂₀O₅SNa, 335.0929; found, 335.0921.

tert-Butyl (2-(((4-methyl-2-oxo-2*H*-chromen-6-yl)sulfonyl)methyl)allyl) carbonate (2d)



From 6-mercapto-4-methyl-2*H*-chromen-2-one (384.4 mg, 2 mmol, 1 equiv) under the general procedure. The crude mixture was subjected to flash silica column chromatography (petroleum ether/EtOAc = 3:1) to yield the title compound **2d** (591.3 mg, 75% yield) as white solid.

¹**H NMR** (400 MHz, CDCl₃): δ 7.77 (s, 1H), 7.74 (s, 2H), 6.41 (s, 1H), 5.38 (s, 1H), 5.01 (s, 1H), 4.59 (s, 2H), 3.89 (s, 2H), 2.46 (s, 3H), 1.43 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 159.1, 153.0, 152.8, 150.9, 140.5, 131.6, 125.7, 124.1, 123.7, 123.6, 118.0, 117.5, 82.7, 67.7, 59.7, 27.7, 18.7.

IR (film): 3084, 2985, 2934, 1743, 1457, 1397, 1272, 1156 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₁₉H₂₃O₇S, 395.1165; found, 395.1163.

tert-Butyl (2-((octylsulfonyl)methyl)allyl) carbonate (2e)

From octane-1-thiol (438.9 mg, 3 mmol, 1 equiv) under the general procedure. The crude mixture was subjected to flash silica column chromatography (petroleum ether/EtOAc = 5:1) to yield the title compound 2e (623.4 mg, 60% yield) as white solid.

¹**H NMR** (400 MHz, CDCl₃): δ 5.51 (s, 1H), 5.38 (s, 1H), 4.77 (s, 2H), 3.73 (s, 2H), 2.97 (t, *J* = 7.6 Hz, 3H), 1.76-1.83 (m, 2H), 1.44 (s, 9H), 1.37-1.41 (m, 2H), 1.20-1.27 (m, 8H), 0.83 (t, *J* = 6.8 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 152.3, 131.8, 122.1, 81.9, 67.4, 55.8, 51.1, 31.0, 28.4, 28.3, 27.9, 27.1, 21.9, 21.2, 13.4.

IR (film): 2927, 2857, 1652, 1463, 1395, 1369, 1286, 1255, 1159 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₁₇H₃₃O₅S, 349.2049; found, 349.2047.

C. References

- [1] Shi, W.; Mao, B.; Xu, J.; Wang, Q.; Wang, W.; Wu, Y.; Li, X.; Guo, H. Org. Lett. 2020, 22, 2675.
- [2] Trost, B. M.; Shinde, A. H.; Wang, Y.; Zuo, Z.; Min, C. ACS Catal. 2020, 10, 1969.
- [3] Zheng, C.; Huang, S.; Liu, Y.; Jiang, C.; Zhang, W.; Fang, G.; Hong, J. Org. Lett. 2020, 22, 4868.
- [4] Trost, B. M.; Zhang, L.; Lam, T. M. Org. Lett. 2018, 20, 3938.
- [5] Khatun, N.; Kim, M. J.; Woo, S. K. Org. Lett. 2018, 20, 6239.

D. General Procedure for the [3+2] Cycloaddition of Sulfone-TMM Donors and Acceptors



A 5 mL thick-wall microwave vial was flame-dried (propane torch for 5 seconds under vacuum) with a magnetic stir bar inside. $Pd_2(dba)_3$ ·CHCl₃ (2.6 mg, 2.5 mol %), (*R*, *R*, *S*, *S*, *R*, *R*)-diamidophosphite ligand L1 (4.2 mg, 6 mol %), 1 (0.1 mmol, 1 equiv), and 2 (0.15 mmol, 1.5 equiv) were added and the system was placed under an atmosphere of argon (balloon). Anhydrous 1,4-dioxane (0.8 mL) was added at room temperature. The resulting mixture was stirred at room temperature for 10 minutes and heated in a 50 °C oil bath for 12 h. Filtration through a plug of Celite gave the crude reaction mixture, which was concentrated in vacuo and purified by silica gel column chromatography (petroleum ether/ethyl acetate) to give the [3+2] cycloaddition adduct **3**.

E. Analysis Data for the Obtained Products

(2*S*, 3*S*)-2-(4-Fluorophenyl)-4-methylene-3-(pyridin-2-ylsulfonyl)spiro[cyclopentane-1,2'-ind ene]-1',3'-dione (3a)



At 0.1 mmol scale, 33.9 mg, 76% yield, dr > 15:1, 99% ee, white foam. Eluting with petroleum ether/EtOAc = 3:1 for column chromatography.

¹**H NMR** (400 MHz, CDCl₃): δ 8.68 (d, *J* = 4.4 Hz, 1H), 8.00 (d, *J* = 7.2 Hz, 1H), 7.70–7.85 (m, 4H), 7.58 (d, *J* = 8.0 Hz, 1H), 7.42–7.46 (m, 1H), 6.89–6.93 (m, 2H), 6.80 (t, *J* = 8.8 Hz, 2H), 5.89 (d, *J* = 7.6 Hz, 1H), 5.60 (d, *J* = 2.4 Hz, 1H), 5.45 (d, *J* = 2.4 Hz, 1H), 3.71 (d, *J* = 7.6 Hz, 1H), 3.33-3.38 (m, 1H), 2.83 (d, *J* = 17.6 Hz, 1H).

¹³**C NMR** (100 MHz, CDCl₃): δ 201.1, 197.0, 162.4 (d, ${}^{1}J_{C-F} = 246.2 \text{ Hz}$), 157.9, 150.1, 142.0, 140.1 (d, ${}^{3}J_{C-F} = 5.5 \text{ Hz}$), 137.8, 136.1 (d, ${}^{2}J_{C-F} = 25.7 \text{ Hz}$), 131.5 (d, ${}^{3}J_{C-F} = 8.1 \text{ Hz}$), 129.1 (d, ${}^{4}J_{C-F} = 3.4 \text{ Hz}$), 127.2, 124.0, 123.4, 122.0, 114.6 (d, ${}^{2}J_{C-F} = 21.3 \text{ Hz}$), 113.5, 66.1, 61.4, 55.0, 35.8.

¹⁹**F NMR** (376 MHz, CDCl₃): δ -113.2 - -113.3 (m, 1F).

IR (film): 2923, 1742, 1705, 1510, 1234 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₂₅H₁₉NO₄SF, 448.1019; found, 448.1010.

Chiral HPLC: 99% ee, (Daicel CHIRALPAK IA, heptane/isopropanol = 80:20, 0.8 mL/min, λ = 254 nm, T_{major} = 23.909 min, T_{minor} = 40.212 min)

 $[\alpha]_{D}^{25}$: -29.92 (*c* = 1.0, CHCl₃).



2-(((15, 25, 3R)-5-Methylene-3-nitro-2-phenylcyclopentyl)sulfonyl)pyridine (3b)



At 0.1 mmol scale, 25.4 mg, 74% yield, dr > 15:1, 93% ee, clear oil. Eluting with petroleum ether/EtOAc = 3:1 for column chromatography.

¹**H** NMR (400 MHz, CDCl₃): δ 8.49 (d, *J* = 4.4 Hz, 1H), 7.38–7.43 (m, 1H), 7.19–7.22 (m, 1H), 7.13 (d, *J* = 8.0 Hz, 1H), 7.00–7.02 (m, 2H), 6.87–6.92 (m, 3H), 6.07–6.14 (m, 1H), 5.72 (d, *J* = 1.2 Hz, 1H), 5.62 (d, *J* = 1.6 Hz, 1H), 5.29 (t, *J* = 7.6 Hz, 1H), 4.34–4.38 (m, 1H), 3.48–3.55 (m, 1H), 3.05–3.12 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): δ 156.8, 149.5, 137.6, 134.1, 131.4, 128.6, 128.1, 127.7, 126.3, 122.1, 121.1, 84.1, 67.5, 51.9, 36.9.

IR (film): 3060, 2920, 1551, 1452, 1428, 1315, 1160 cm⁻¹

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₁₇H₁₇N₂O₄S, 345.0909; found, 345.0897.

Chiral HPLC: 93% ee, (Daicel CHIRALPAK IB, heptane/isopropanol = 90:10, 0.8 mL/min, λ =

254 nm, $T_{\text{major}} = 50.861 \text{ min}$, $T_{\text{minor}} = 42.913 \text{ min}$)



 $[\alpha]_{D}^{23}$: = +9.92 (*c* = 0.5, CH₂Cl₂).

2-(((15, 25, 3R)-5-Methylene-3-nitro-2-(phenanthren-9-yl)cyclopentyl)sulfonyl)pyridine (3c)



At 0.05 mmol scale, 21.1 mg, 95% yield, dr > 15:1, 99% ee, yellow solid. Eluting with petroleum ether/EtOAc = 3:1 for column chromatography.

¹**H NMR** (400 MHz, CDCl₃): δ 8.31–8.36 (m, 2H), 7.87–7.89 (m, 1H), 7.84 (s, 1H), 7.75–7.78 (m, 1H), 7.60–7.62 (m, 2H), 7.51–7.55 (m, 3H), 6.69 (d, *J* = 7.6 Hz, 1H), 6.51–6.54 (m, 1H), 6.42–6.49 (m, 1H), 6.35–6.39 (m, 1H), 5.95 (s, 1H), 5.77 (d, *J* = 1.6 Hz, 1H), 5.60 (d, *J* = 7.6 Hz, 1H), 4.94–4.98 (m, 1H), 3.62–3.69 (m, 1H), 3.20–3.28 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): δ 155.2, 148.2, 135.6, 133.5, 130.4, 130.1, 130.0, 129.7, 129.1, 127.6, 127.1, 127.1, 126.7, 126.6, 125.7, 125.1, 123.4, 122.8, 121.8, 121.5, 121.2, 83.7, 65.9, 48.4, 36.7. IR (film): 3064, 2921, 1557, 1451, 1372, 1314, 1164 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₂₅H₂₁N₂O₄S, 445.1222; found, 445.1217.

Chiral HPLC: 99% ee, ((Daicel CHIRALPAK IB, heptane/ethyl acetate = 80:20, 0.8 mL/min, $\lambda =$

254 nm, $T_{\text{major}} = 23.414 \text{ min}$, $T_{\text{minor}} = 42.054 \text{ min}$)

 $[\alpha]_{D}^{23}$: = -21.67 (*c* =1.0, CH₂Cl₂).

2

40.967 BB

400 Peak RetTime Type Width Height Area Area [min] mAU ŧ [min] *s MAU 1 of o 23,920 BV 0.7244 2.45402e4 506.07626 49.3647 1

2.2329 2.51719e4

151.35538

50,6353



Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	mAU *s	[mAU]	de
1	23.414	BB	0.7755	7.06977e4	1327.87976	99.7719
2	42.054	BB	0.7235	161.63367	2.67645	0.2281

 $\label{eq:2-((15, 25, 3R)-5-Methylene-2-(4-(methylthio)phenyl)-3-nitrocyclopentyl) sulfonyl) pyridine$

(**3d**)



At 0.1 mmol scale, 35.5 mg, 91% yield, dr > 15:1, 99% ee, clear oil. Eluting with petroleum ether/EtOAc = 3:1 for column chromatography.

¹**H NMR** (400 MHz, CDCl₃): δ 8.49–8.51 (m, 1H), 7.48–7.52 (m, 1H), 7.26–7.29 (m, 1H), 7.15 (d, *J* = 8.0 Hz, 1H), 6.91 (d, *J* = 8.0 Hz, 2H), 6.72 (d, *J* = 8.4 Hz, 2H), 6.02–6.09 (m, 1H), 5.74 (d, *J* = 1.2 Hz, 1H), 5.63 (d, *J* = 1.2 Hz, 1H), 5.27 (d, *J* = 7.6 Hz, 1H), 4.28–4.33 (m, 1H), 3.48–3.54 (m, 1H), 3.06–3.14 (m, 1H), 2.35 (m, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 156.8, 149.5, 138.5, 137.7, 134.0, 129.0, 127.9, 126.1, 125.6, 122.0, 121.1, 84.0, 67.8, 51.5, 36.9, 15.2.

IR (film): 2924, 1552, 1497, 1314, 1161 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₁₈H₁₉N₂O₄S₂, 391.0786; found, 391.0776.

Chiral HPLC: 99% ee, (Daicel CHIRALPAK IB, heptane/isopropanol = 80:20, 0.8 mL/min, λ = 254 nm, T_{major} = 32.132 min, T_{minor} = 28.700 min)

 $[\alpha]_{D}^{23}$: = +21.98 (*c* =1.0, CHCl₃).



2-(((15, 25, 3R)-5-Methylene-3-nitro-2-(p-tolyl)cyclopentyl)sulfonyl)pyridine (3e)



At 0.1 mmol scale, 27.9 mg, 78% yield, dr > 15:1, 99% ee, white solid. Eluting with petroleum ether/EtOAc = 3:1 for column chromatography.

¹**H NMR** (400 MHz, CDCl₃): δ 8.49–8.50 (m, 1H), 7.40–7.44 (m, 1H), 7.23–7.26 (m, 1H), 7.13 (d, *J* = 7.6 Hz, 1H), 6.89 (d, *J* = 7.6 Hz, 2H), 6.68 (d, *J* = 8.0 Hz, 2H), 6.05–6.12 (m, 1H), 5.73 (d, *J* = 1.2 Hz, 1H), 5.62 (d, *J* = 1.2 Hz, 1H), 5.26 (d, *J* = 7.6 Hz, 1H), 4.31–4.36 (m, 1H), 3.48–3.55 (m, 1H), 3.05–3.13 (m, 1H), 2.12 (s, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 156.9, 149.5, 137.4, 137.2, 134.2, 128.8, 128.4, 128.3, 125.9, 122.1, 121.0, 84.1, 67.9, 51.6, 36.9, 20.8.

IR (film): 360, 2922, 2854, 1553, 1317, 1109 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₁₈H₁₉N₂O₄S, 359.1066; found, 359.1057.

Chiral HPLC: 99% ee, (Daicel CHIRALPAK IB, heptane/isopropanol = 90:10, 0.8 mL/min, λ =

254 nm, $T_{\text{major}} = 45.439 \text{ min}$, $T_{\text{minor}} = 35.586 \text{ min}$)



 $[\alpha]_{D}^{23}$: +19.48 (*c* = 1.0, CHCl₃).

2-(((15, 25, 3R)-2-(3-Methoxyphenyl)-5-methylene-3-nitrocyclopentyl)sulfonyl)pyridine (3f)



At 0.1 mmol scale, 28.8 mg, 77% yield, dr > 15:1, 99% ee, clear oil. Eluting with petroleum ether/EtOAc = 2:1 for column chromatography.

¹**H NMR** (400 MHz, CDCl₃): δ 8.53–8.54 (m, 1H), 7.46–7.50 (m, 1H), 7.23–7.27 (m, 2H), 6.88 (t, *J* = 7.6 Hz, 1H), 6.69 (d, *J* = 7.6 Hz, 1H), 6.47–6.49 (m, 2H), 6.06–6.14 (m, 1H), 5.78 (s, 1H), 5.66 (s, 1H), 5.29 (d, *J* = 7.6 Hz, 1H), 4.33–4.38 (m, 1H), 3.63 (s, 3H), 3.51–3.57 (m, 1H), 3.07–3.14 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): δ 156.4, 154.4, 146.8, 134.8, 131.4, 130.4, 126.6, 123.6, 119.5, 118.6, 118.0, 111.7, 111.0, 81.5, 65.0, 52.3, 49.2, 34.3.

IR (film): 2932, 2844, 1551, 1430, 1315, 1160 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₁₈H₁₉N₂O₅S, 375.1015; found, 375.1014.

Chiral HPLC: 99% ee, (Daicel CHIRALPAK IA, heptane/isopropanol = 85:15, 0.8 mL/min, λ =

220 nm, $T_{\text{major}} = 26.990 \text{ min}$) [α] \mathbf{p}^{23} : -9.06 (c = 0.5, CH₂Cl₂).



2-(((1*S*, 2*S*, 3*R*)-2-(Benzo[*b*]thiophen-3-yl)-5-methylene-3-nitrocyclopentyl)sulfonyl)pyridine (3g)



At 0.05 mmol scale, 14.0 mg, 70% yield, dr > 15:1, 99% ee, clear oil. Eluting with petroleum ether/EtOAc = 3:1 for column chromatography.

¹**H NMR** (400 MHz, CDCl₃): δ 7.81 (d, J = 3.6 Hz, 1H), 7.37–7.44 (m, 3H), 7.24–7.34 (m, 1H),

7.15–7.23 (m, 3H), 6.65–6.68 (m, 1H), 6.12–6.19 (m, 1H), 5.91 (s, 1H), 5.57 (s, 1H), 5.50 (d, J =

8.0 Hz, 1H), 4.49–4.54 (m, 1H), 3.54–3.56 (m, 1H), 3.15–3.21 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): δ 155.1, 148.6, 139.5, 137.4, 136.4, 133.6, 127.2, 125.3, 124.6, 123.9,

122.2, 121.5, 120.7, 85.1, 65.7, 46.5, 36.5.

IR (film): 2930, 1553, 1428, 1314, 1162 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₁₉H₁₇N₂O₄S₂, 401.0630; found, 401.0622.

Chiral HPLC: 99% ee, (Daicel CHIRALPAK IB, heptane/isopropanol = 80:20, 0.8 mL/min, λ =

254 nm, $T_{\text{major}} = 21.006 \text{ min}$, $T_{\text{minor}} = 34.881 \text{ min}$).

 $[\alpha]_{D}^{23}$: = -21.36 (*c* = 1.0, CHCl₃).



2-(((15, 25, 3R)-2-Hexyl-5-methylene-3-nitrocyclopentyl)sulfonyl)pyridine (3h)



At 0.05 mmol scale, 9.1 mg, 51% yield, dr > 15:1, 99% ee, clear oil. Eluting with petroleum ether/EtOAc = 3:1 for column chromatography.

¹**H NMR** (400 MHz, CDCl₃): δ 8.79 (d, *J* = 4.4 Hz, 1H), 7.90–7.99 (m, 2H), 7.53–7.56 (m, 1H), 5.31–5.37 (m, 1H), 5.00 (s, 1H), 4.80 (d, *J* = 7.2 Hz, 1H), 4.56 (s, 1H), 3.28–3.33 (m, 1H), 3.09–3.12 (m, 1H), 2.78–2.83 (m, 1H), 2.02–2.12 (m, 1H), 1.67–1.73 (m, 1H), 1.35–1.50 (m, 1H), 1.20–1.29 (m, 7H), 0.84 (t, *J* = 7.0 Hz, 3H).

¹³C NMR (400 MHz, CDCl₃): δ 156.6, 150.2, 138.9, 137.8, 127.5, 123.2, 117.9, 88.6, 67.8, 49.7, 36.7, 31.4, 29.1, 28.4, 27.9, 22.5, 14.0.

IR (film): 3038, 2929, 1551, 1315, 1160 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₁₇H₂₅N₂O₄S, 353.1535; found, 353.1524.

Chiral HPLC: 99% ee, (Daicel CHIRALPAK IC, heptane/isopropanol = 90:10, 0.8 mL/min, λ =

254 nm, $T_{\text{minor}} = 27.747 \text{ min}$, $T_{\text{major}} = 35.849 \text{ min}$).

 $[\alpha]_{D}^{23}$: +0.33 (*c* = 0.5, CHCl₃).



N-((1*S*, 2*R*, 5*R*)-3-Methylene-5-nitro-2-(pyridin-2-ylsulfonyl)cyclopentyl)-1,1diphenylmethanimine (3i)



At 0.1 mmol scale, 26.8 mg, 60% yield, dr > 15:1, 99% ee, clear oil. Eluting with petroleum ether/EtOAc = 3:1 for column chromatography.

¹**H** NMR (400 MHz, CD₂Cl₂): δ 8.40–8.41 (m, 1H), 7.94 (d, *J* = 7.6 Hz, 1H), 7.47–7.49 (m, 3H), 7.29–7.37 (m, 2H), 7.10–7.21 (m, 6H), 6.82–6.85 (m, 1H), 5.81 (q, *J* = 9.2 Hz, 1H), 5.67 (d, *J* = 1.2 Hz, 1H), 5.53 (d, *J* = 1.2 Hz, 1H), 5.02 (d, *J* = 7.6 Hz, 1H), 4.49–4.54 (m, 1H), 3.42–3.49 (m, 1H), 2.89–2.97 (m, 1H).

¹³C NMR (100 MHz, CD₂Cl₂): δ 172.4, 158.9, 148.9, 137.9, 137.5, 135.1, 134.1, 130.9, 129.1, 128.7, 127.5, 127.2, 125.8, 121.3, 120.1, 87.8, 68.5, 67.4, 35.3.

IR (film): 3361, 2927, 1551, 1316, 1112 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₂₄H₂₂N₃O₄S, 448.1331; found, 448.1328.

Chiral HPLC: 99% ee, (Daicel CHIRALPAK IA, heptane/isopropanol = 90:10, 0.8 mL/min, λ = 254 nm, T_{minor} = 24.506 min, T_{major} = 17.173 min).

 $[\alpha]_D^{23}$: -61.59 (c = 0.5 CH₂Cl₂).



(S)-2-([1,1'-Biphenyl]-4-yl)-4-methyl-3-(pyridin-2-ylsulfonyl)cyclopent-3-ene-1,1-dicarbonitrile (3j')



At 0.05 mmol scale, 15.8 mg, 74% yield, 97% ee, clear oil. Eluting with petroleum ether/EtOAc = 3:1 for column chromatography.

¹**H NMR** (400 MHz, CDCl₃): δ 8.65 (d, *J* = 4.8 Hz, 1H), 7.53–7.58 (m, 2H), 7.24–7.48 (m, 8H), 7.01 (d, *J* = 7.6 Hz, 2H), 4.98 (s, 1H), 3.53 (d, *J* = 17.6 Hz, 1H), 3.39 (d, *J* = 18.0 Hz, 1H), 2.52 (s, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 158.0, 153.8, 150.2, 142.2, 139.8, 137.6, 134.8, 131.4, 128.9, 128.8, 127.8, 127.6, 127.1, 127.0, 122.2, 116.1, 112.8, 61.7, 49.6, 38.2, 15.9.

IR (film): 3031, 2924, 1638, 1325, 1166 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₂₅H₂₀N₃O₂S, 426.1276; found, 426.1266.

Chiral HPLC: 97% ee, (Daicel CHIRALPAK IB, heptane/isopropanol = 80:20, 0.8 mL/min, λ =

254 nm, $T_{\text{minor}} = 27.179 \text{ min}$, $T_{\text{major}} = 29.417 \text{ min}$).

 $[\alpha]_{D}^{23}$: -133.26 (*c* = 1.0, CHCl₃).



N-((1*S*, 2*R*, 5*R*)-3-Methylene-5-nitro-2-(pyrimidin-2-ylsulfonyl)cyclopentyl)-1,1diphenylmethanimine (3k)



At 0.1 mmol scale, 42.1 mg, 94% yield, dr > 15:1, 99% ee, clear oil. Eluting with petroleum ether/EtOAc = 1:1 for column chromatography.

¹**H** NMR (400 MHz, CD₂Cl₂): δ 8.47 (d, *J* = 5.2 Hz, 2H), 7.50–7.51 (m, 3H), 7.34–7.38 (m, 1H), 7.12–7.21 (m, 6H), 6.68 (t, *J* = 6.8 Hz, 1H), 5.72–5.81 (m, 2H), 5.57 (d, *J* = 1.2 Hz, 1H), 5.11 (d, *J* = 7.6 Hz, 1H), 4.60–4.64 (m, 1H), 3.44–3.51 (m, 1H), 2.92–3.00 (m, 1H).

¹³C NMR (100 MHz, CD₂Cl₂): δ 172.5, 166.6, 157.8, 137.6, 134.8, 133.7, 131.2, 129.2, 128.9,

128.7, 127.7, 127.1, 121.8, 120.3, 87.5, 68.4, 67.5, 35.2.

IR (film): 3361, 2927, 1551, 1316, 1112 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₂₃H₂₁N₄O₄S, 449.1284; found, 449.1289.

Chiral HPLC: 99% ee, (Daicel CHIRALPAK IB, heptane/isopropanol = 80:20, 0.8 mL/min, λ = 254 nm, T_{minor} = 29.910 min, T_{major} = 35.845 min).

 $[\alpha]_{D}^{23}$: -92.99 (*c* = 1.0, CH₂Cl₂).



5R)-3-Methylene-5-nitro-2-(phenylsulfonyl)cyclopentyl)-1,1-

N-((1*S*, 2*R*, diphenylmethanimine (3l)



At 0.05 mmol scale, 21.0 mg, 94% yield, dr > 15:1, 98% ee, clear oil. Eluting with petroleum ether/EtOAc = 4:1 for column chromatography.

¹H NMR (400 MHz, CDCl₃): δ 7.84–7.87 (m, 2H), 7.39–7.43 (m, 7H), 7.26–7.31 (m, 3H), 7.15–

7.17 (m, 2H), 6.85–6.86 (m, 1H), 5.68–5.75 (m, 1H), 5.36–5.38 (m, 2H), 4.52–4.56 (m, 1H), 3.96–

3.98 (m, 1H), 3.34–3.41 (m, 1H), 2.81–2.87 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): δ 139.7, 138.0, 135.8, 135.5, 133.1, 130.9, 129.3, 129.2, 129.0, 128.8,

128.4, 127.8, 126.8, 120.1, 88.3, 72.8, 67.7, 35.1.

IR (film): 3030, 2921, 1550, 1446, 1308, 1145 cm⁻¹.

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₂₅H₂₃N₂O₄S, 447.1379; found, 447.1370.

Chiral HPLC: 98% ee, (Daicel CHIRALPAK IA, heptane/isopropanol = 85:15, 0.8 mL/min, λ =

254 nm, $T_{\text{minor}} = 24.226 \text{ min}$, $T_{\text{major}} = 34.381 \text{ min}$).

 $[\alpha]_D^{23}$: -43.69 (*c* = 1.0, CHCl₃)



6-(((1*R*, 2*S*, 3*R*)-2-((bis(4-Methoxyphenyl)methylene)amino)-5-methylene-3nitrocyclopentyl)sulfonyl)-4-methyl-2*H*-chromen-2-one (3m)



At 0.1 mmol scale, 42.9 mg, 73% yield, dr > 15:1, 98% ee, clear oil. Eluting with petroleum ether/EtOAc = 1:1 for column chromatography.

¹**H NMR** (400 MHz, CD₂Cl₂): δ 7.77–7.78 (m, 1H), 7.67–7.69 (m, 1H), 7.37 (d, *J* = 8.4 Hz, 1H), 7.15 (d, *J* = 8.8 Hz, 2H), 6.96 (d, *J* = 8.4 Hz, 2H), 6.82 (d, *J* = 8.4 Hz, 2H), 6.67 (d, *J* = 8.8 Hz, 2H), 6.19 (s, 1H), 5.71 (q, *J* = 8.0 Hz, 1H), 5.61 (s, 1H), 5.51 (s, 1H), 4.52–4.56 (m, 1H), 4.26 (d, *J* = 7.6 Hz, 1H), 3.83 (s, 3H), 3.79 (s, 3H), 3.40–3.46 (m, 1H), 2.86–2.94 (m, 1H), 2.21 (s, 3H).

¹³C NMR (100 MHz, CD₂Cl₂): δ 171.9, 161.8, 160.1, 159.0, 152.7, 150.8, 143.5, 135.0, 130.7, 130.7, 128.2, 125.2, 122.9, 122.8, 120.0, 117.1, 114.1, 112.8, 88.1, 72.9, 67.4, 55.3, 55.2, 35.2, 18.1.
IR (film): 3073, 2962, 1730, 1602, 1550, 1509, 1312, 1251, 1138cm⁻¹;

HRMS (ESI-TOF, m/z): [M+H]⁺ Calcd. for C₃₁H₂₉N₂O₈S, 589.1645; found, 589.1650.

Chiral HPLC: 99% ee, (Daicel CHIRALPAK IB, heptane/isopropanol = 70:30, 0.8 mL/min, λ = 254 nm, T_{major} = 28.420 min).

 $[\alpha]_{D}^{23}$: -232.75 (*c* = 2.0, CH₂Cl₂)



F. X-Ray Crystallographic Data

The obtained compound 3e (20 mg, 99% ee) was dissolved in CH₂Cl₂ (0.2 mL) in a 20 mL vial, then petroleum ether (15 mL) was added slowly. The resulted two-phase mixture allowed to open to air to volatilize the solvent via a needle hole on the cap. Then the colorless crystal of 3e was formed. The X-ray crystallographic structures for 3e. ORTEP representation with 50% probability thermal ellipsoids. Solvent are omitted for clarity. Crystal data have been deposited to CCDC, number 2056297.



Empirical formula	$C_{18}H_{18}N_2O_4S$
Formula weight	358.40
Temperature	120 (2) K
Wavelength	1.54178 Å
Crystal system, space group	Monoclinic; P2 ₁
Unit cell dimensions	a = 8.8478(6) Å $alpha = 90$ deg. $b = 10.5745(7)$ Å $beta = 96.515(2)$ deg. $c = 8.9386(6)$ Å $gamma = 90$ deg.
Volume	830.90(10) Å ³
Z, Calculated density	2, 1.433 g.cm ⁻³

Absorption coefficient	1.965 mm ⁻¹
F(000)	376
Crystal size	$0.201\times0.141\times0.068\ mm^3$
Theta range for data collection	4.980 to 70.394°
Limiting indices	$-10 \le h \le 10, -12 \le k \le 12, -10 \le l \le 10$
Reflections collected / unique	$16968 \ / \ 3139 \ [R_{int} = 0.0365]$
Completeness to theta = 67.679°	100.0 %
Refinement method	Full-matrix least-squares on F ²
Refinement method Data / restraints / parameters	Full-matrix least-squares on F ² 3139 / 1 / 227
Refinement method Data / restraints / parameters Goodness-of-fit on F ²	Full-matrix least-squares on F ² 3139 / 1 / 227 1.063
Refinement methodData / restraints / parametersGoodness-of-fit on F2Final R indices [I>2sigma(I)]	Full-matrix least-squares on F^2 3139 / 1 / 227 1.063 $R_1 = 0.0260$, w $R_2 = 0.0664$
Refinement methodData / restraints / parametersGoodness-of-fit on F2Final R indices [I>2sigma(I)]R indices (all data)	Full-matrix least-squares on F^2 $3139 / 1 / 227$ 1.063 $R_1 = 0.0260, wR_2 = 0.0664$ $R_1 = 0.0261, wR_2 = 0.0665$
Refinement methodData / restraints / parametersGoodness-of-fit on F2Final R indices [I>2sigma(I)]R indices (all data)Absolute structure parameter	Full-matrix least-squares on F^2 $3139 / 1 / 227$ 1.063 $R_1 = 0.0260, wR_2 = 0.0664$ $R_1 = 0.0261, wR_2 = 0.0665$ $0.067(6)$

G. NMR Spectra of New Compounds

¹H NMR (400 MHz, CDCl₃) spectrum for 1k



¹³C NMR (100 MHz, CDCl₃) spectrum for 1k







¹³C NMR (100 MHz, CDCl₃) spectrum for 2a





¹³C NMR (100 MHz, CDCl₃) spectrum for 2b





¹³C NMR (100 MHz, CDCl₃) spectrum for 2c



¹H NMR (400 MHz, CDCl₃) spectrum for 2d



¹³C NMR (100 MHz, CDCl₃) spectrum for 2d





¹H NMR (400 MHz, CDCl₃) spectrum for 2e



-8500

-8000 -7500

¹³C NMR (100 MHz, CDCl₃) spectrum for 2e



¹H NMR (400 MHz, CDCl₃) spectrum for 3a



¹³C NMR (100 MHz, CDCl₃) spectrum for 3a



¹⁹F NMR (376 MHz, CDCl₃) spectrum for 3a



¹H NMR (400 MHz, CDCl₃) spectrum for 3b







¹H NMR (400 MHz, CDCl₃) spectrum for 3c



¹³C NMR (100 MHz, CDCl₃) spectrum for 3c



¹H NMR (400 MHz, CDCl₃) spectrum for 3d



¹³C NMR (100 MHz, CDCl₃) spectrum for 3d



¹H NMR (400 MHz, CDCl₃) spectrum for 3e



¹³C NMR (100 MHz, CDCl₃) spectrum for 3e



¹H NMR (400 MHz, CDCl₃) spectrum for 3f



¹³C NMR (100 MHz, CDCl₃) spectrum for 3f



¹H NMR (400 MHz, CDCl₃) spectrum for 3g





¹H NMR (400 MHz, CDCl₃) spectrum for 3h



37

¹³C NMR (100 MHz, CDCl₃) spectrum for 3h



¹H NMR (400 MHz, CD₂Cl₂) spectrum for 3i



¹³C NMR (100 MHz, CD₂Cl₂) spectrum for 3i



¹H NMR (400 MHz, CDCl₃) spectrum for 3j'







¹H NMR (400 MHz, CD₂Cl₂) spectrum for 3k







¹H NMR (400 MHz, CDCl₃) spectrum for 3l



¹³C NMR (100 MHz, CDCl₃) spectrum for 3l



¹H NMR (400 MHz, CD₂Cl₂) spectrum for 3m



¹³C NMR (100 MHz, CD₂Cl₂) spectrum for 3m

